Eli Lilly and Company LLY reported fourth-quarter 2024 adjusted earnings per share (“EPS”) of $5.32, which beat the Zacks Consensus Estimate of $5.03 per share. Earnings rose 114% year over ...

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin drug strategy.

While Eli Lilly missed on both the top and bottom lines in its Q3 financial results, a look at its sales figures -- and especially sales growth -- would make many other pharmaceutical companies ...

Eli Lilly’s diabetes drugs in short supply: FDA The FDA added Eli Lilly’s diabetes drugs Mounjaro and Trulicity to its list of medications in short supply Dec. 15.

Trulicity sales fell 22% to $1.30 billion. Guidance: Eli Lilly forecasts fiscal year 2024 sales of $45.4 billion—$46 billion, compared to prior guidance of $45.4 billion—$46.6 billion and ...

Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Low Risk High Growth Stocks to Buy. Amid carrying on new studies, the ...

--Eli Lilly and Company today announced its financial results for the third quarter of 2024.. "Lilly had another strong growth quarter in Q3, with total revenue increasing by 42% after excluding ...

Among some of Lilly's other bigger sellers, sales of diabetes treatment Trulicity dropped 22.2% to $1.3 billion, as "competitive dynamics" offset higher prices, but that topped expectations of $1. ...

INN Insider News INN Insider News RSS Get our newsletter Order Prints May 14, 2025 INN Insider News ...